Skip to main content
v2026.11,986 entries · CC-BY 4.0

MR-Guided Focused Ultrasound (MRgFUS): Technology, Indications, and Clinical Economics

A comprehensive guide to MR-guided focused ultrasound (MRgFUS): acoustic physics, FDA indications, Medicare reimbursement under CPT 61715, and clinical use.

Written and maintained by CASRAI Editorial Board

Published

On this page

Magnetic resonance-guided focused ultrasound (MRgFUS) is an incisionless therapeutic technology that combines high-intensity focused acoustic energy with real-time magnetic resonance imaging to non-invasively ablate targeted tissue structures, open biological barriers, or modulate neural circuits. By concentrating hundreds to thousands of individual ultrasound waves onto a focal millimeter-scale volume, the system raises target tissue temperatures to induce precise coagulative necrosis while continuous MR thermometry tracks thermal dosage and protects adjacent healthy anatomy.

This page describes products and general use; it is not medical advice.

What is MRgFUS?

Magnetic resonance-guided focused ultrasound (MRgFUS) represents the convergence of high-intensity therapeutic acoustics and diagnostic magnetic resonance imaging. Unlike conventional diagnostic sonography—which emits low-power acoustic waves through hand-held transducers to visualize anatomical structures as described in our guide to ultrasound machines—MRgFUS delivers concentrated therapeutic energy. The system harnesses geometric acoustic convergence: multiple intersecting acoustic beams pass through intervening tissue layers and converge at a defined focal coordinate deep within the body. At this focal point, acoustic energy transforms into thermal energy, elevating local tissue temperatures above 55°C to produce irreversible coagulative necrosis within seconds.

The integration of magnetic resonance imaging serves two critical functions during the procedure: stereotactic anatomical guidance and quantitative thermometry. Before acoustic delivery begins, high-resolution diagnostic MRI sequences identify the target volume with sub-millimeter precision. During therapeutic energy delivery (sonication), phase-difference MR sequences quantify temperature changes in real time across the treatment area using the temperature-dependent proton resonance frequency shift (PRFS) of water molecules. This dual capability allows clinical teams to verify focal target accuracy at sub-lethal test temperatures before escalating energy to permanent ablation levels.

In modern biomedical practice, MRgFUS is utilized across neurosurgery, oncology, and gynecology. The technology received its earliest regulatory authorizations for treating symptomatic uterine fibroids by ablating benign smooth muscle tumors. However, its most prominent clinical impact occurs in functional neurosurgery, specifically for medication-refractory movement disorders including essential tremor and Parkinson’s disease. By eliminating the necessity of trephination (cutting a burr hole through the skull) or penetrating brain tissue with mechanical probes, MRgFUS establishes an incisionless alternative for central nervous system interventions.

How MRgFUS Works in Practice

The engineering architecture of transcranial MRgFUS overcomes a central challenge in applied biophysics: propagating acoustic waves through the human calvarium without distorting the focal target or overheating cranial bone. Bone exhibits high acoustic attenuation, absorbing ultrasound energy roughly twenty times more effectively than soft brain tissue. Furthermore, variations in skull thickness, density, and curvature introduce severe phase aberrations that scatter and defocus ultrasound beams.

To overcome these physical limitations, intracranial MRgFUS platforms employ a hemispherical helmet transducer containing 1,024 individual piezoelectric elements operating at sub-megahertz frequencies (typically around 650 kHz). Prior to treatment, the patient undergoes a high-resolution volumetric computed tomography (CT) scan of the cranium. Acoustic modeling algorithms analyze the CT data to map local bone density and skull thickness at every entry point. The system calculates individual phase and amplitude offsets for all 1,024 transducer elements, canceling out aberrations caused by the skull. When activated, the phase-corrected acoustic waves constructively interfere at the chosen coordinate within the brain while remaining diffuse across the scalp and skull surface.

Active thermal management is maintained throughout the treatment envelope. A flexible silicone membrane seals the space between the transducer helmet and the patient’s shaved scalp, circulating chilled, degassed water maintained at approximately 15°C to 20°C. Degassing the water removes microscopic air bubbles that would otherwise cause cavitation or acoustic reflections, while active chilling dissipates heat absorbed by cranial bone. For deeper explorations into transducer geometry and element arrangements, readers can consult our overview of ultrasound probe types and their clinical characteristics.

The standard clinical and technical workflow for intracranial MRgFUS encompasses five systematic stages:

  1. Pre-treatment Planning and Cranial CT: Volumetric bone-window CT imaging characterizes cranial geometry and calculates the patient’s skull density ratio (SDR) across the acoustic path.
  2. Stereotactic Frame Placement and Acoustic Coupling: A rigid stereotactic headframe is secured under local anesthesia to prevent movement, and the degassed water circulation membrane is sealed against the scalp.
  3. Intraoperative MR Target Alignment: The patient is positioned inside the MRI bore, where 3D T2-weighted and diffusion tensor imaging sequences register anatomical landmarks and map white matter tracts adjacent to the target nucleus.
  4. Sub-lethal Verification Sonications: Low-power sonications deliver energy sufficient to raise focal temperature to 45°C–48°C. This allows the clinical team to verify target localization, confirm physiological tremor suppression, and ensure no off-target sensory or motor deficits occur before permanent lesioning.
  5. Therapeutic Coagulative Ablation: Full-power sonications deliver sustained acoustic energy, elevating focal temperatures to 55°C–60°C for 10 to 20 seconds to achieve permanent coagulative necrosis, verified by post-sonication T2 and diffusion-weighted MRI scans.

What Does a Neurologist Do for Essential Tremors?

A neurologist specializing in movement disorders guides the systematic diagnosis, medical optimization, and procedural evaluation for patients presenting with essential tremor (ET). Essential tremor is a progressive neurological condition characterized by kinetic and postural shaking, predominantly affecting the hands and forearms during intentional activities such as writing, eating, or holding utensils. The neurologist’s primary responsibility is establishing an accurate differential diagnosis, ruling out Parkinsonian tremors, dystonic tremors, metabolic tremors, and drug-induced tremors through structured neurological examination and objective functional assessments.

Initial clinical management directed by a neurologist focuses on conservative pharmacotherapy. First-line medical therapy traditionally employs oral medications including propranolol (a non-selective beta-adrenergic blocker) and primidone (an anticonvulsant). When first-line agents fail or produce intolerable adverse effects—such as bradycardia, hypotension, severe fatigue, or cognitive slowing—the neurologist may evaluate secondary pharmaceutical options, including topiramate, gabapentin, or benzodiazepines. In cases where tremor is localized to the head or voice, targeted botulinum toxin injections may be administered into affected muscle groups.

Despite rigorous pharmacological trials, clinical studies document that approximately 30% to 50% of essential tremor patients fail to achieve adequate functional symptom control or discontinue medications due to systemic side effects. When tremor severity causes persistent disability in daily living activities—such as feeding, drinking, and hygiene—the neurologist evaluates the patient for advanced interventions. The neurologist administers standardized tremor rating scales (such as the Fahn-Tolosa-Marin Clinical Rating Scale for Tremor, CRST), orders neuroimaging to evaluate structural anatomy, and coordinates with specialized neurosurgical teams to determine whether the patient is a candidate for MRgFUS or Deep Brain Stimulation (DBS).

Comparison of Surgical and Incisionless Interventions for Movement Disorders

When pharmacotherapy fails to control disabling essential tremor or Parkinsonian motor complications, clinicians and researchers evaluate three primary interventional modalities: MR-guided focused ultrasound (MRgFUS), Deep Brain Stimulation (DBS), and stereotactic radiofrequency (RF) thalamotomy. Each approach modulates or ablates the tremor circuit within the cerebello-thalamo-cortical pathway, primarily targeting the ventral intermediate nucleus (VIM) of the thalamus or the globus pallidus internus (GPi).

The following comparison table synthesizes the operational, anatomical, and hardware characteristics of these three therapeutic approaches:

Clinical Attribute MR-Guided Focused Ultrasound (MRgFUS) Deep Brain Stimulation (DBS) Radiofrequency (RF) Thalamotomy
Surgical Invasiveness Incisionless; no craniotomy, burr holes, or skin incisions Invasive; burr hole craniotomy, lead tunneling, subcutaneous generator placement Invasive; burr hole craniotomy and brain probe insertion
Mechanism of Action Acoustic thermal ablation (>55°C coagulative necrosis) Continuous high-frequency electrical neuromodulation Radiofrequency thermal probe ablation (70°C–80°C coagulative necrosis)
Hardware Implantation None; zero indwelling foreign bodies Permanent brain leads, extension cables, and neurostimulator pulse generator None; probe is removed immediately following lesion creation
Reversibility and Adjustment Irreversible permanent thermal lesion; fixed effect Reversible; electrical stimulation parameters can be adjusted or turned off Irreversible permanent thermal lesion; fixed effect
Bilateral Capability Primarily unilateral; staged contralateral procedures require rigorous screening Simultaneous or staged bilateral stimulation widely practiced Strictly unilateral due to severe risk of dysarthria and pseudobulbar palsy
Infection and Hardware Risk Zero risk of device infection, lead migration, or wire fracture Risk of surgical site infection, erosion, lead breakage, and battery depletion Low risk of infection; zero long-term hardware complication risk
Imaging Guidance Real-time intraoperative MRI guidance and PRFS thermometry Pre-operative MRI/CT fusion paired with microelectrode recording (MER) Stereotactic frame registration with intraoperative test stimulation
Recovery Time Outpatient or 24-hour observation; rapid functional recovery Multi-day inpatient hospitalization; multiple programming visits required 1 to 3 days inpatient hospitalization

As summarized in the table, the chief clinical advantage of MRgFUS is its incisionless nature, which completely eliminates surgical wound infections, intracranial hardware migrations, and repeat battery-replacement operations. Conversely, Deep Brain Stimulation remains the preferred modality for patients requiring simultaneous bilateral tremor control or those whose symptoms evolve, requiring post-operative parameter adjustments. For broader context on clinical ultrasound instrumentation and cost frameworks, see our detailed guide on therapeutic ultrasound and medical technology economics.

How Much Does MRgFUS Cost?

The total cost of MRgFUS treatment encompasses clinical consultation, neuroimaging screening, stereotactic facility expenses, and professional physician fees. For insured patients in the United States, out-of-pocket expenses depend heavily on payer classification, supplemental insurance policies, and annual deductibles. Because MRgFUS represents a specialized medical procedure requiring substantial institutional capital, understanding coding and reimbursement frameworks is essential for healthcare facilities and patients alike.

From a regulatory and billing standpoint, a major transition occurred on January 1, 2025. The American Medical Association (AMA) officially retired temporary Category III tracking code 0398T and transitioned intracranial MRgFUS stereotactic ablation to permanent Category I CPT code 61715. Category I CPT designation signifies widespread clinical acceptance, established procedural efficacy, and standardized billing nationwide. CPT code 61715 encompasses intracranial stereotactic lesion ablation utilizing magnetic resonance image-guided high-intensity focused ultrasound, including intraoperative stereotactic guidance, trajectory planning, and stereotactic frame placement.

Medicare Part B covers MRgFUS across all 50 states for patients diagnosed with medication-refractory essential tremor who meet specific clinical criteria. Facility reimbursement under the Medicare Hospital Outpatient Prospective Payment System (OPPS) maps to Ambulatory Payment Classification (APC) 5463 (Level 3 Neurostimulator and Related Procedures), yielding average national base facility payments typically ranging between $10,000 and $12,500, adjusted for local hospital wage indices. Physician professional fees under the Medicare Physician Fee Schedule (MPFS) average approximately $1,100 to $1,300. For beneficiaries with Original Medicare Part B, Medicare reimburses 80% of the approved amount once the annual Part B deductible is satisfied, while secondary Medigap insurance policies generally cover the remaining 20% coinsurance.

For self-pay, international, or commercially uninsured patients, medical centers establish comprehensive bundled package rates for MRgFUS neurosurgeries. In United States academic medical centers, bundled cash rates generally range from $25,000 to $45,000, covering pre-procedure MR/CT screening, intraoperative MRI suite utilization, physician services, and same-day recovery observation. While this capital outlay is substantial, economic evaluations note that MRgFUS avoids recurring lifetime costs associated with DBS hardware maintenance, such as subcutaneous battery replacements and frequent neurostimulator programming consultations.

What Are the Cons of Focused Ultrasound?

Despite the substantial clinical benefit of non-invasive treatment, MR-guided focused ultrasound possesses distinct limitations, anatomical prerequisites, and potential adverse effects that clinicians and patients must evaluate carefully before selecting the procedure.

The foremost technical constraint is the requirement for adequate cranial acoustic penetration, quantified by the skull density ratio (SDR). The SDR is calculated from pre-procedural bone-window CT scans as the ratio of cortical bone density to trabecular (cancellous) bone density. Because cancellous bone is porous and irregular, it scatters ultrasound energy and absorbs thermal heat rapidly. Patients with an SDR below 0.40 to 0.45 are generally contraindicated for transcranial MRgFUS because the calvarium absorbs excessive acoustic energy, risking scalp or cranial thermal injury before therapeutic ablation temperatures can be achieved at the deep thalamic target.

A second major consideration is the permanence and irreversibility of the ablation. In contrast to Deep Brain Stimulation—where electrodes can be turned off or adjusted if neurological side effects arise—MRgFUS creates an irreversible thermal lesion. If the focal ablation extends slightly beyond the ventral intermediate nucleus into adjacent sensory or motor pathways (such as the ventral caudal nucleus or the internal capsule), permanent sensory alterations or motor deficits can occur.

Clinical trial data and post-market safety registries highlight several common procedural and post-procedural adverse events:

  • Sensory Paresthesias: Tingling, numbness, or altered sensation in the fingers, lips, or face occurring in 15% to 25% of patients post-procedure, caused by transient perilesional edema or thermal spread to adjacent thalamic sensory nuclei. While most resolve within months, mild sensory numbness may persist in a minority of patients.
  • Gait Ataxia and Imbalance: Transient unsteadiness, tandem walking impairment, or mild cerebellar ataxia reported in 10% to 30% of treated individuals, typically peaking during the first week due to local edema before subsiding.
  • Intraoperative Discomfort: Sonicatory headaches, scalp heat, dizziness, and nausea during energy delivery, managed with active water cooling and systemic analgesics.
  • Bilateral Treatment Limitations: Performing simultaneous bilateral thermal thalamotomies carries severe risks of speech impairment (dysarthria) and swallowing dysfunction (dysphagia). Consequently, bilateral MRgFUS is restricted to staged contralateral procedures separated by at least nine months, following strict clinical assessment.
  • Claustrophobia and Frame Immobilization: Patients must tolerate lying supine inside the high-field MRI bore for two to three hours with a rigid stereotactic frame bolted to the skull, excluding individuals with severe claustrophobia or inability to remain still.

Where MRgFUS Matters for Research and Clinical Infrastructure

Implementing an MRgFUS operational service represents a multi-disciplinary commitment requiring coordination across neurosurgery, neuroradiology, medical physics, and clinical engineering. Within clinical research, MRgFUS is advancing beyond thermal ablation into non-thermal mechanical modalities, such as pulsed focused ultrasound for targeted blood-brain barrier opening (BBBO). Research organizations such as the Focused Ultrasound Foundation coordinate international multi-center trials evaluating BBBO to deliver therapeutic monoclonal antibodies, viral vectors, and chemotherapeutic agents directly into central nervous system tissues for glioblastoma and neurodegenerative conditions.

From a facility and equipment procurement perspective, clinical sites must ensure compatibility between the focused ultrasound apparatus and institutional magnetic resonance infrastructure. MRgFUS transducers are engineered for specific MRI manufacturer platforms and bore field strengths (primarily 1.5 Tesla and 3.0 Tesla systems). In addition, facilities must install dedicated high-purity water degassing and chilling circulators, specialized non-ferromagnetic stereotactic patient positioning systems, and radiofrequency-shielded penetrations through the MRI suite wave guides. For biomedical researchers and engineers working within the discipline of biomedical engineering, maintaining rigorous quality assurance protocols—including acoustic phantom calibrations, hydrophone beam profiling, and thermometry validation—is vital for clinical efficacy and patient safety.

The data table below compares the clinical, regulatory, and billing attributes of primary intracranial neurosurgical and acoustic modalities, tracing each parameter to official regulatory filings and health technology assessments.

Frequently asked questions

What is MRgFUS?

Magnetic resonance-guided focused ultrasound (MRgFUS) is an incisionless medical technology that converges high-intensity ultrasound beams onto targeted anatomical structures inside the body under real-time magnetic resonance imaging guidance. The acoustic energy raises target tissue temperatures to produce permanent thermal ablation, while MR thermometry continuously monitors thermal dosage to protect surrounding structures.

What does a neurologist do for essential tremors?

A neurologist diagnoses essential tremor, conducts objective functional assessments, and initiates first-line pharmacotherapy using medications such as propranolol or primidone. If oral medications fail to control disabling tremor or cause intolerable adverse effects, the neurologist coordinates patient evaluation for advanced device-based therapies, including MRgFUS and Deep Brain Stimulation.

How much does MRgFUS cost?

Under Medicare Part B, MRgFUS is covered nationally for medication-refractory essential tremor under Category I CPT code 61715, with average outpatient hospital facility payments ranging between $10,000 and $12,500 and professional physician fees averaging $1,100 to $1,300, subject to standard coinsurance. Self-pay bundled rates at United States academic medical centers typically range between $25,000 and $45,000.

What are the cons of focused ultrasound?

The primary cons of focused ultrasound include its anatomical exclusion of patients with low skull density ratios (SDR under 0.40), the irreversibility of the permanent thermal lesion, and procedural risks such as transient or mild persistent numbness (paresthesias) and gait unsteadiness. In addition, simultaneous bilateral treatments are avoided due to severe risks of dysarthria and swallowing impairment.

Is MRgFUS treatment permanent?

Yes, MRgFUS produces a permanent therapeutic lesion. When focused ultrasound waves elevate target tissue temperatures above 55°C to 60°C, immediate thermal coagulative necrosis occurs, resulting in irreversible destruction of the hyperactive tremor-generating cells in the thalamus.

Can MRgFUS treat both sides of the brain?

MRgFUS can be performed on both sides of the brain only as a staged contralateral procedure. Because simultaneous bilateral thalamotomy carries unacceptable risks of severe speech and swallowing disorders, regulatory guidelines require waiting at least nine months following the initial procedure before treating the second side.

Sources

Data: Clinical and Regulatory Parameters of Therapeutic Intracranial Modalities

Comparative evaluation of intracranial neurosurgical and therapeutic ultrasound modalities compiled from FDA Premarket Approvals, CMS reimbursement schedules, and clinical literature.

Period covered: 2024/2026. Coverage: United States.

Clinical and Regulatory Parameters of Therapeutic Intracranial Modalities
ModalityInvasiveness LevelPrimary MechanismCurrent CPT Billing CodeFDA Regulatory ClassAdjustability ProfileStandard Hospital Stay (hours)
MR-Guided Focused Ultrasound (MRgFUS)Incisionless (transcranial)Convergent acoustic thermal ablationCPT 61715Class III (PMA)Permanent focal lesion (non-adjustable)4
Deep Brain Stimulation (DBS)Invasive (burr hole craniotomy & subcutaneous implant)High-frequency electrical neuromodulationCPT 61867Class III (PMA)Programmable and reversible24
Stereotactic Radiofrequency ThalamotomyInvasive (burr hole probe insertion)Electrode thermal coagulative necrosisCPT 61720Class II / III (510k/PMA)Permanent focal lesion (non-adjustable)24
Stereotactic Radiosurgery (Gamma Knife)Non-invasive (closed cranial delivery)Ionizing gamma radiation focal necrosisCPT 77371Class II (510k)Delayed permanent lesion (non-adjustable)4

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about MR-Guided Focused Ultrasound (MRgFUS): Technology, Indications, and Clinical Economics

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →